blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3102237

EP3102237 - COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  08.10.2021
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  30.10.2020
FormerGrant of patent is intended
Status updated on  15.06.2020
FormerExamination is in progress
Status updated on  18.10.2019
FormerRequest for examination was made
Status updated on  11.11.2016
Most recent event   Tooltip19.12.2025Lapse of the patent in a contracting state
New state(s): TR		published on 21.01.2026  [2026/04]
Applicant(s)For all designated states
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, DE 19803 / US
For all designated states
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
[2016/50]
Inventor(s)01 / LEOPOLD, Lance
1801 Augustine Cut-off
Wilmington, Delaware 19803 / US
02 / KAUFMAN, David
Merck Research Laboratories
UG3CD-28
P.O. Box 1000
North Wales, Pennsylvania 19454-1099 / US
 [2016/50]
Representative(s)Cornish, Kristina Victoria Joy
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2020/49]
Former [2016/50]Briscoe, Paul Brian, et al
Kilburn & Strode LLP
20 Red Lion Street
London WC1R 4PJ / GB
Application number, filing date15746743.203.02.2015
[2016/50]
WO2015US14247
Priority number, dateUS201461935714P04.02.2014         Original published format: US 201461935714 P
[2016/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015119944
Date:13.08.2015
Language:EN
[2015/32]
Type: A1 Application with search report 
No.:EP3102237
Date:14.12.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 13.08.2015 takes the place of the publication of the European patent application.
[2016/50]
Type: B1 Patent specification 
No.:EP3102237
Date:02.12.2020
Language:EN
[2020/49]
Search report(s)International search report - published on:US13.08.2015
(Supplementary) European search report - dispatched on:EP05.07.2017
ClassificationIPC:A61K31/4245, A61K39/395, A61K45/06, A61P35/00
[2017/31]
CPC:
A61K31/4245 (EP,IL,KR,US); A61K39/395 (RU); A61K39/3955 (EP,IL,KR,US);
C07K16/2803 (IL,US); A61K39/39558 (EP,IL,KR,US); A61K45/06 (EP,IL,KR,US);
A61P35/00 (EP,IL,KR,RU,US); C07D271/00 (IL); C07K16/2818 (EP,IL,KR,US);
C07K16/3023 (IL,US); A61K2039/505 (EP,IL,KR,US); A61K2039/545 (EP,IL,KR,US);
A61K2300/00 (IL,KR); C07K2317/24 (EP,IL,KR,US); C07K2317/565 (IL,US);
C07K2317/76 (EP,IL,KR,US) (-)
C-Set:
A61K31/4245, A61K2300/00 (US,EP);
A61K39/39558, A61K2300/00 (EP,US);
A61K39/3955, A61K2300/00 (US,EP)
Former IPC [2016/50]A61K39/395
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/50]
Extension statesBA30.08.2016
ME30.08.2016
TitleGerman:KOMBINATION AUS EINEM PD-1-ANTAGONISTEN UND EINEM IDO1-INHIBITOR ZUR BEHANDLUNG VON KREBS[2016/50]
English:COMBINATION OF A PD-1 ANTAGONIST AND AN IDO1 INHIBITOR FOR TREATING CANCER[2016/50]
French:COMBINAISON D'UN ANTAGONISTE DE PD-1 ET D'UN INHIBITEUR DE IDO1 POUR TRAITER LE CANCER[2016/50]
Entry into regional phase30.08.2016National basic fee paid 
30.08.2016Search fee paid 
30.08.2016Designation fee(s) paid 
30.08.2016Examination fee paid 
Examination procedure30.08.2016Examination requested  [2016/50]
30.08.2016Date on which the examining division has become responsible
31.01.2018Amendment by applicant (claims and/or description)
17.10.2019Despatch of a communication from the examining division (Time limit: M04)
26.02.2020Reply to a communication from the examining division
16.06.2020Communication of intention to grant the patent
26.10.2020Fee for grant paid
26.10.2020Fee for publishing/printing paid
26.10.2020Receipt of the translation of the claim(s)
Opposition(s)03.09.2021No opposition filed within time limit [2021/45]
Fees paidRenewal fee
10.02.2017Renewal fee patent year 03
14.02.2018Renewal fee patent year 04
13.02.2019Renewal fee patent year 05
13.02.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.02.2015
AL02.12.2020
AT02.12.2020
CY02.12.2020
CZ02.12.2020
DK02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
MK02.12.2020
MT02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SI02.12.2020
SK02.12.2020
SM02.12.2020
TR02.12.2020
LU03.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
[2026/04]
Former [2024/41]HU03.02.2015
AL02.12.2020
AT02.12.2020
CY02.12.2020
CZ02.12.2020
DK02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
MK02.12.2020
MT02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SI02.12.2020
SK02.12.2020
SM02.12.2020
LU03.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2024/22]HU03.02.2015
AL02.12.2020
AT02.12.2020
CY02.12.2020
CZ02.12.2020
DK02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
MK02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SI02.12.2020
SK02.12.2020
SM02.12.2020
LU03.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2023/30]HU03.02.2015
AL02.12.2020
AT02.12.2020
CY02.12.2020
CZ02.12.2020
DK02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SI02.12.2020
SK02.12.2020
SM02.12.2020
LU03.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2023/27]HU03.02.2015
AL02.12.2020
AT02.12.2020
CZ02.12.2020
DK02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SI02.12.2020
SK02.12.2020
SM02.12.2020
LU03.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2022/34]AL02.12.2020
AT02.12.2020
CZ02.12.2020
DK02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SI02.12.2020
SK02.12.2020
SM02.12.2020
LU03.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2022/23]AL02.12.2020
AT02.12.2020
CZ02.12.2020
DK02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SI02.12.2020
SK02.12.2020
SM02.12.2020
LU03.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2022/10]AL02.12.2020
AT02.12.2020
CZ02.12.2020
DK02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SI02.12.2020
SK02.12.2020
SM02.12.2020
LU03.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
PT05.04.2021
Former [2021/49]AL02.12.2020
AT02.12.2020
CZ02.12.2020
DK02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SI02.12.2020
SK02.12.2020
SM02.12.2020
LU03.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2021/47]AL02.12.2020
AT02.12.2020
CZ02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SK02.12.2020
SM02.12.2020
LU03.02.2021
CH28.02.2021
LI28.02.2021
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2021/45]AL02.12.2020
AT02.12.2020
CZ02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SK02.12.2020
SM02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2021/42]AT02.12.2020
CZ02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SK02.12.2020
SM02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
IS02.04.2021
PT05.04.2021
Former [2021/41]AT02.12.2020
CZ02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
MC02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SK02.12.2020
SM02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
PT05.04.2021
Former [2021/37]AT02.12.2020
CZ02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SK02.12.2020
SM02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
PT05.04.2021
Former [2021/36]CZ02.12.2020
EE02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SK02.12.2020
SM02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
PT05.04.2021
Former [2021/35]CZ02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
NL02.12.2020
PL02.12.2020
RO02.12.2020
RS02.12.2020
SE02.12.2020
SK02.12.2020
SM02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
PT05.04.2021
Former [2021/34]CZ02.12.2020
FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
NL02.12.2020
PL02.12.2020
RS02.12.2020
SE02.12.2020
SM02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
PT05.04.2021
Former [2021/33]FI02.12.2020
HR02.12.2020
LT02.12.2020
LV02.12.2020
NL02.12.2020
PL02.12.2020
RS02.12.2020
SE02.12.2020
SM02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
PT05.04.2021
Former [2021/32]FI02.12.2020
HR02.12.2020
LV02.12.2020
NL02.12.2020
PL02.12.2020
RS02.12.2020
SE02.12.2020
SM02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
Former [2021/30]FI02.12.2020
HR02.12.2020
LV02.12.2020
NL02.12.2020
PL02.12.2020
RS02.12.2020
SE02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
Former [2021/28]FI02.12.2020
HR02.12.2020
LV02.12.2020
PL02.12.2020
RS02.12.2020
SE02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
Former [2021/25]FI02.12.2020
LV02.12.2020
PL02.12.2020
RS02.12.2020
SE02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
Former [2021/24]FI02.12.2020
LV02.12.2020
RS02.12.2020
SE02.12.2020
BG02.03.2021
NO02.03.2021
GR03.03.2021
Former [2021/23]FI02.12.2020
LV02.12.2020
RS02.12.2020
SE02.12.2020
NO02.03.2021
GR03.03.2021
Former [2021/22]FI02.12.2020
RS02.12.2020
NO02.03.2021
Former [2021/20]FI02.12.2020
Documents cited:Search[Y] WO2012135408  (MERCK SHARP & DOHME et al.) [Y] 7 * claim 1 *
 [XP] WO2014066834  (UNIV CHICAGO et al.) [XP] 1-6,8-11,17 * page 2, paragraph 6 - page 3, paragraph 8 * * pages 44-45, paragraph 161 * * page 50, paragraph 174 * * examples 1-3, 5, 7, 9, 11, 13, 15, 18, 20, 21, 23 * * page 131; table 4 * * figures 3, 18 *
 [Y]   RIKKE B HOLMGAARD ET AL: "Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4", vol. 210, no. 7, 1 July 2013 (2013-07-01), pages 1389 - 1402, XP002770451, ISSN: 0022-1007, Retrieved from the Internet [Y] 1-17 * abstract * * page 1390, column 1, paragraph 5 - column 2, paragraph 1 * * page 1391, column 2, paragraph 2 * * figure 3 *

DOI:   http://dx.doi.org/10.1084/jem.20130066
 [Y]   STEFANI SPRANGER ET AL: "Rational combinations of immunotherapeutics that target discrete pathways", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 1, no. 1, 1 January 2013 (2013-01-01), London, UK, pages 16, XP055237414, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-16 [Y] 1-17 * page 5, column 2, paragraph 2 - page 6, column 2, paragraph 1 * * page 8, column 2, paragraph 2 - page 9, column 1, paragraph 3 * * figure 4 *

DOI:   http://dx.doi.org/10.1186/2051-1426-1-16
 [Y]   TOPALIAN SUZANNE L ET AL: "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 366, no. 26, 28 June 2012 (2012-06-28), pages 2443 - 2454, XP002767416, ISSN: 1533-4406 [Y] 1-17 * abstract *

DOI:   http://dx.doi.org/10.1056/NEJMoa1200690
 [XP]   ANONYMOUS: "A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)", 30 June 2014 (2014-06-30), XP055381569, Retrieved from the Internet [retrieved on 20170614] [XP] 1-17 * the whole document *
 [XP]   ANONYMOUS: "A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)", 29 December 2014 (2014-12-29), XP055381565, Retrieved from the Internet [retrieved on 20170614] [XP] 1-17 * the whole document *
International search[XY] US2014023663  (COMBS ANDREW P et al.) [X] 1, 4, 7, 8, 15 * entire document *[Y] 2, 3, 9, 16, 17
 [Y] US2010266617  (CARVEN GREGORY JOHN et al.) [Y] 2, 3, 9, 16, 17 * entire document *
 [A]   PILOTTE ET AL.: "Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase", PNAS, vol. 109, no. 107, 14 February 2012 (2012-02-14), pages 2497 - 2502, XP055219624 [A] 1-4, 7-9, 15-17 * . entire document *

DOI:   http://dx.doi.org/10.1073/pnas.1113873109
 [A]   DOLUSIC ET AL.: "Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008-2012", EXPERT OPIN. THER PATENTS, vol. 23, no. 7, 2013, pages 1 - 15, XP009172214 [A] 1-4, 7-9, 15-17 * . entire document *

DOI:   http://dx.doi.org/10.1517/13543776.2013
 [A]   ROEHRIG ET AL.: "Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors", J. MED. CHEM., vol. 2010, no. 53, 7 January 2010 (2010-01-07), pages 1172 - 1189, XP002622031 [A] 1-4, 7-9, 15-17 * . entire document *

DOI:   http://dx.doi.org/10.1021/jm9014718
by applicantUS2013075932
 US4816567
 US7488802
 US7521051
 US8008449
 US8354509
 US8168757
 WO2004004771
 WO2004072286
 WO2004056875
 US2011271358
 WO2008156712
 WO2013019906
 WO2010077634
 US8383796
 WO2010027827
 WO2011066342
 US8088803
 WO2012135408
 US6329511
   CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877 - 883
   STATES, D.J. ET AL., METHODS, vol. 219, 1991, pages 555 - 565
   KABAT, ADV. PROT. CHEM., vol. 32, 1978, pages 1 - 75
   KABAT ET AL., J. BIOL. CHEM., vol. 252, 1977, pages 6609 - 6616
   CHOTHIA ET AL., J MOL. BIOL., vol. 196, 1987, pages 901 - 917
   CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
   AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
   T. HIGUCHIV STELLA: "A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article "Prodrugs as Novel Delivery Systems", pages: 224
   CHEN, B.J., CLIN CANCER RES, vol. 19, 2013, pages 3462 - 3473
   ALTSCHUL, S.F. ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
   GISH, W., NATURE GENET., vol. 3, 1993, pages 266 - 272
   MADDEN, T.L., METH. ENZYMOL., vol. 266, 1996, pages 131 - 141
   ALTSCHUL, S.F., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
   ZHANG, J., GENOME RES., vol. 7, 1997, pages 649 - 656
   WOOTTON, J.C. ET AL., COMPUT. CHEM., vol. 17, 1993, pages 149 - 163
   HANCOCK, J.M., COMPUT. APPL. BIOSCI., vol. 10, 1994, pages 67 - 70
   SCHWARTZ, R.M. ET AL.: "Atlas of Protein Sequence and Structure", vol. 5, 1978, NATL. BIOMED. RES. FOUND., article "Matrices for detecting distant relationships", pages: 353 - 358
   HENIKOFF, S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 10919
   ALTSCHUL, S.F. ET AL., J. MOL. EVOL., vol. 36, 1993, pages 290 - 300
   KARLIN, S. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268
   KARLIN, S., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877
   DEMBO, A., ANN. PROB., vol. 22, 1994, pages 2022 - 2039
   ALTSCHUL, S.F.: "Theoretical and Computational Methods in Genome Research", 1997, PLENUM, article "Evaluating the statistical significance of multiple distinct local alignments", pages: 1 - 14
   CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
   KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
   MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
   PRESTA, J. ALLERGY CLIN. IMMUNOL., vol. 116, 2005, pages 731
   WHO DRUG INFORMATION, vol. 27, no. 1, 2013, pages 161 - 162
   THOMPSON, R. H. ET AL., PNAS, vol. 101, no. 49, 2004, pages 17174 - 17179
   THOMPSON, R. H. ET AL., CANCER RES., vol. 66, 2006, pages 3381 - 3385
   GADIOT, J. ET AL., CANCER, vol. 117, 2011, pages 2192 - 2201
   TAUBE, J. M. ET AL., SCI TRANSL MED, vol. 4, 2012, pages 127ra37
   TOPLIAN, S. L. ET AL., NEW ENG. J MED., vol. 366, no. 26, 2012, pages 2443 - 2454
   E.A. ET AL., EUR. J CANCER, vol. 45, 2009, pages 228 - 247
   W. A. WEBER, J. NUCL. MED., vol. 50, 2009, pages 1S - 10S
   WOLCHOK JD ET AL.: "Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria", CLIN CANCER RES., vol. 15, no. 23, 2009, pages 7412 - 7420
   NISHINO MGIOBBIE-HURDER AGARGANO MSUDA MRAMAIYA NHHODI FS: "Developing a Common Language for Tumor Response to Immunotherapy: Immune-related Response Criteria using Unidimentional measurements", CLIN CANCER RES., vol. 19, no. 14, 2013, pages 3936 - 3943, XP055157316, DOI: 10.1158/1078-0432.CCR-13-0895

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0895
   "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
   "Journal of Pharmaceutical Science", vol. 66, 1977, pages: 2
   AGNEW, CHEM. INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186
   VAUGHAN ET AL., NATURE BIOTECHNOL., vol. 14, 1996, pages 309 - 314
   LE DOUSSAL ET AL., J. IMMUNOL., vol. 146, 1991, pages 169 - 175
   WU: "Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases", vol. 217, 1993, ACADEMIC PRESS
   GHOSH ET AL., NEW ENGL. J. MED., vol. 349, 2003, pages 427 - 434
   MILGROM ET AL., NEW ENGL. J. MED., vol. 341, 1999, pages 1966 - 1973
   SLAMON ET AL., NEW ENGL. J. MED., vol. 344, 2001, pages 783 - 792
   BENIAMINOVITZ ET AL., NEW ENGL. J. MED., vol. 343, 2000, pages 1594 - 1602
   "Physicians' Desk Reference", November 2002, MEDICAL ECONOMICS COMPANY
   HEROLD ET AL., NEW ENGL. J. MED., vol. 346, 2002, pages 1692 - 1698
   LIU ET AL., J. NEUROL. NEUROSURG. PSYCH., vol. 67, 1999, pages 451 - 456
   PORTIELJI ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 52, pages 133 - 144
   SAMBROOKFRITSCHMANIATIS: "Molecular Cloning, A Laboratory Manual", 1982, COLD SPRING HARBOR LABORATORY PRESS
   SAMBROOKRUSSELL: "Current Protocols in Molecular Biology", vol. 1-4, 2001, COLD SPRING HARBOR LABORATORY PRESS, pages: 384 - 391
   CARPENTER ET AL., J. IMMUNOL., vol. 165, 2000, pages 6205
   TANG ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 27371 - 27378
   HARLOWLANE: "Antibodies A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS, pages: 139 - 243
   GIBELLINI ET AL., J. IMMUNOL., vol. 160, 1998, pages 3891 - 3898
   BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684
   FOOTEWINTER, J. MOL. BIOL., vol. 224, 1992, pages 487 - 499
   BARBAS, NATURE MEDICINE, vol. 1, 1995, pages 837 - 839
   MENDEZ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 - 156
   HOOGENBOOMCHAMES, IMMUNOL. TODAY, vol. 21, 2000, pages 371 - 377
   KAY ET AL.: "Phage Display of Peptides and Proteins: A Laboratory Manual", 1996, ACADEMIC PRESS
   KAITHAMANA ET AL., J. IMMUNOL., vol. 162, 1999, pages 2804 - 2811
   MEYAARD ET AL., IMMUNITY, vol. 7, 1997, pages 283 - 290
   WRIGHT ET AL., IMMUNITY, vol. 13, 2000, pages 233 - 242
   EVERTS ET AL., J. IMMUNOL., vol. 168, pages 883 - 889
   OWENS ET AL.: "Flow Cytometry Principles for Clinical Laboratory Practice", 1994, JOHN WILEY AND SONS
   SHAPIRO: "Practical Flow Cytometry", 2003, MOLECULAR PROBES, INC., article "Molecular Probesy"
   SIGMA-ALDRICH, CATALOGUE, 2003
   VON HEIJNE, NUCLEIC ACIDS RES., vol. 14, 1986, pages 4683 - 4690
   MENNE ET AL., BIOINFORMATICS, vol. 16, 2000, pages 741 - 742
   WREN ET AL., COMPUT. METHODS PROGRAMS BIOMED., vol. 68, 2002, pages 177 - 181
   MENNE ET AL., BIOINFORMATICS APPLICATIONS NOTE, vol. 16, 2000, pages 741 - 742
   VON HEIJNE, EUR. J. BIOCHEM., vol. 133, 1983, pages 17 - 21
   SHARPE, A.HWHERRY, E.J.AHMED R.FREEMAN G.J.: "The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection", NATURE IMMUNOLOGY, vol. 8, 2007, pages 239 - 245
   DONG H ET AL.: "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion", NAT MED., vol. 8, no. 8, August 2002 (2002-08-01), pages 793 - 800, XP002397368, DOI: 10.1038/nm730

DOI:   http://dx.doi.org/10.1038/nm730
   YANG ET AL.: "PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro", INVEST OPHTHALMOL VIS SCI., vol. 49, no. 6, June 2008 (2008-06-01), pages 2518 - 2525, XP055412241, DOI: 10.1167/iovs.07-1606

DOI:   http://dx.doi.org/10.1167/iovs.07-1606
   GHEBEH ET AL.: "The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors", NEOPLASIA, vol. 8, 2006, pages 190 - 198, XP008091677, DOI: 10.1593/neo.05733

DOI:   http://dx.doi.org/10.1593/neo.05733
   HAMANISHI J ET AL.: "Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer", PROCEEDING OF THE NATIONAL ACADEMY OF SCIENCES, vol. 104, 2007, pages 3360 - 3365
   THOMPSON RH ET AL.: "Significance of B7-H1 overexpression in kidney cancer. Clinical genitourin", CANCER, vol. 5, 2006, pages 206 - 211
   NOMI, T.SHO, M.AKAHORI, T. ET AL.: "Clinical significance and therapeutic potential of the programmed death- 1 ligand/programmed death-1 pathway in human pancreatic cancer", CLINICAL CANCER RESEARCH, vol. 13, 2007, pages 2151 - 2157, XP002533527, DOI: 10.1158/1078-0432.CCR-06-2746

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-06-2746
   OHIGASHI Y ET AL.: "Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand 2 expression in human esophageal cancer", CLIN. CANCER RESEARCH, vol. 11, 2005, pages 2947 - 2953, XP002419631, DOI: 10.1158/1078-0432.CCR-04-1469

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-04-1469
   INMAN ET AL.: "PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression", CANCER, vol. 109, 2007, pages 1499 - 1505
   SHIMAUCHI T ET AL.: "Augmented expression of programmed death-1 in both neoplastic and nonneoplastic CD4+ T-cells in adult T-cell Leukemia/ Lymphoma", INT. J. CANCER, vol. 121, 2007, pages 2585 - 2590
   GAO ET AL.: "Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma", CLINICAL CANCER RESEARCH, vol. 15, 2009, pages 971 - 979
   NAKANISHI J.: "Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers", CANCER IMMUNOL IMMUNOTHER., vol. 56, 2007, pages 1173 - 1182, XP019514169, DOI: 10.1007/s00262-006-0266-z

DOI:   http://dx.doi.org/10.1007/s00262-006-0266-z
   HINO ET AL.: "Tumor cell expression of programmed cell death-1 is a prognostic factor for malignant melanoma", CANCER, vol. 00, 2010, pages 1 - 9
   GHEBEH H.: "Foxp3+ tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy", BMC CANCER, vol. 8, 2008, pages 57, XP021034690
   AHMADZADEH M ET AL.: "Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired", BLOOD, vol. 114, 2009, pages 1537 - 1544, XP055648069
   THOMPSON RH ET AL.: "PD-1 is expressed by tumor infiltrating cells and is associated with poor outcome for patients with renal carcinoma", CLINICAL CANCER RESEARCH, vol. 15, 2007, pages 1757 - 1761, XP055613062, DOI: 10.1158/1078-0432.CCR-06-2599

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-06-2599
   PLATTEN, M.W. WICKB.J. VAN DEN EYNDE: "Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion", CANCER RES, vol. 72, no. 21, 2012, pages 5435 - 5440, XP055512932, DOI: 10.1158/0008-5472.CAN-12-0569

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-12-0569
   MUNN, D.H.: "Blocking IDO activity to enhance anti-tumor immunity", FRONT BIOSCI (ELITE ED), vol. 4, 2012, pages 734 - 745
   WEBER, W.P. ET AL.: "Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines", EUR J IMMUNOL, vol. 36, no. 2, 2006, pages 296 - 304
   UYTTENHOVE, C. ET AL.: "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase", NAT MED, vol. 9, no. 10, 2003, pages 1269 - 1274, XP002559000, DOI: 10.1038/nm934

DOI:   http://dx.doi.org/10.1038/nm934
   LIU, X.: "Selective inhibition of IDOl effectively regulates mediators of antitumor immunity", BLOOD, vol. 115, no. 17, 2010, pages 3520 - 3530, XP055054663, DOI: 10.1182/blood-2009-09-246124

DOI:   http://dx.doi.org/10.1182/blood-2009-09-246124
   LEE, G.K.: "Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division", IMMUNOLOGY, vol. 107, no. 4, 2002, pages 452 - 460
   BONANNO, G. ET AL.: "Indoleamine 2,3-dioxygenase 1 (IDOl) activity correlates with immune system abnormalities in multiple myeloma", J TRANSL MED, vol. 10, 2012, pages 247, XP021134211, DOI: 10.1186/1479-5876-10-247

DOI:   http://dx.doi.org/10.1186/1479-5876-10-247
   HOLMGAARD, R.B. ET AL.: "Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4", J EXP MED, vol. 210, no. 7, 2013, pages 1389 - 1402, XP055545183, DOI: 10.1084/jem.20130066

DOI:   http://dx.doi.org/10.1084/jem.20130066
   YUE, E.W. ET AL.: "Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model", J MED CHEM, vol. 52, no. 23, 2009, pages 7364 - 7367, XP055049180, DOI: 10.1021/jm900518f

DOI:   http://dx.doi.org/10.1021/jm900518f
   KOBLISH, H.K. ET AL.: "Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors", MOL CANCER THER, vol. 9, no. 2, 2010, pages 489 - 498, XP055131665, DOI: 10.1158/1535-7163.MCT-09-0628

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-09-0628
   LIU, X. ET AL.: "Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy", CURR CANCER DRUG TARGETS, vol. 9, no. 8, 2009, pages 93 8 - 52
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.